Lexicon Pharmaceuticals (LXRX) Receivables (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Receivables data on file, last reported at $11.8 million in Q1 2026.

• On a quarterly basis, Receivables fell 75.17% year-over-year to $11.8 million in Q1 2026; TTM through Mar 2026 was $11.8 million, a 75.17% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 31.36% from the prior year.
• Receivables for Q1 2026 stood at $11.8 million, up from $2.4 million in the prior quarter.
• Over the last five years, Receivables for LXRX reached as high as $47.4 million in Q1 2025 and fell as low as $28000.0 in Q4 2022.
• Historically, Receivables has averaged $4.7 million across 5 years, with a median of $1.5 million in 2024.
• Across the five-year window, Receivables sank 78.62% in 2022 and surged 3507.14% in 2023, its largest moves.
• Year by year, Receivables stood at $28000.0 in 2022, then jumped by 3507.14% to $1.0 million in 2023, then surged by 243.86% to $3.5 million in 2024, then tumbled by 31.36% to $2.4 million in 2025, then jumped by 394.09% to $11.8 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $11.8 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.